Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    6 0 0 0

Joint Bone Spine
Volume 71, n° 6
pages 475-480 (novembre 2004)
Doi : 10.1016/j.jbspin.2004.07.005
Received : 13 July 2004 ;  accepted : 13 July 2004
Should patients with recent-onset polyarthritis receive aggressive treatment?

Bernard Combe
Immuno-Rheumatology Department, Lapeyronie Teaching Hospital, 31, avenue du Doyen Gaston Giraud, 34295 Montpellier cedex 5, France 

*Corresponding author. Tel.: +33-4-67-33-87-10; Fax: +33-4-67-33-73-11.

Lecture presented at the 17th Meeting of the Société Française de Rhumatologie, CNIT – La Défense, Paris, novembre 2004.


The diagnostic and therapeutic management of rheumatoid arthritis has benefited considerably in recent years not only from the introduction of new treatments (including new disease-modifying antirheumatic drugs, new combinations of these drugs, and TNF inhibitors), but also from the development of new concepts. Important new concepts include the use of novel diagnostic approaches, very early management within the first 3–6 months of symptom onset, periodic assessments of clinical disease activity based on objective clinical criteria and radiographic progression, and earlier use of aggressive treatments. The goal is to induce a clinical remission, thereby preventing radiographic deterioration. These concepts are firmly supported by sound scientific data. At present, patients at risk for progression to severe rheumatoid arthritis must be identified early on, and disease activity and progression must be monitored closely. This should enable patients with highly progressive disease to receive aggressive treatment (e.g., a combination of disease-modifying antirheumatic drugs or biological therapy) very early on with the goal of minimizing joint destruction and subsequent functional impairments.

The full text of this article is available in PDF format.

Keywords : Rheumatoid arthritis, Recent-onset polyarthritis, Disease-modifying antirheumatic drugs, Anti-TNF agents, Drug combinations

© 2004  Elsevier SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline